Have you been affected by peripheral T-cell lymphoma?
Published on: 30 May 2018Lymphoma Canada is seeking the views of peripheral T-cell lymphoma patients who have experience of pralatrexate or belinostat.
Lymphoma Canada is seeking the views of anyone who has, or has had, peripheral T-cell lymphoma and has been treated with pralatrexate or belinostat. The charity has also launched a general survey for people with experience of this type of lymphoma.
The aim of the two surveys is to learn more about the experiences of this patient population. Responses will help Lymphoma Canada prepare the patient input required for its submissions to the pan-Canadian Oncology Drug Review (pCODR). pCODR uses this information to help them make recommendations to Canadian public drug plans regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
The surveys, which are open until midnight (PT) on Friday 8 June, should take approximately 15 minutes to complete.
Complete the survey for people with experience of pralatrexate (Folotyn) or belinostat (Beleodaq)
Complete the peripheral T-cell lymphoma general patient survey